The role of fibrates in chronic kidney disease and diabetes mellitus

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Huang, Y. & Hu, Y. Lipid-lowering agents in chronic kidney disease: do fibrates have a role? Nat. Rev. Cardiol. http://dx.doi.org/10.1038/nrcardio.2013.15-c1.

  2. 2

    Kahn, M. R. et al. Management of cardiovascular disease in patients with kidney disease. Nat. Rev. Cardiol. 10, 261–273 (2013).

  3. 3

    Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).

  4. 4

    Davis, T. M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54, 280–290 (2011).

  5. 5

    Mychaleckyj, J. C. et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35, 1008–1014 (2012).

Download references

Author information

Correspondence to Mark R. Kahn.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article